Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Sponsored by Psoriasis Treatment Center of Central New Jersey
About this study
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.
Where this study is enrolling
- I'm interested
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Who can participate
Inclusion criteria
- ✓Male or female adult ≥ 18 years of age;
- ✓Diagnosis of chronic plaque-type
- ✓Patient with 2-10% BSA
- ✓Physician Global Assessment of 2 or greater
- ✓Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion criteria
- ✕˂2 or \>10% BSA
- ✕PGA \<2
- ✕Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.